Trial Profile

Phase III trial of SABER-bupivacaine (Posidur) for pain relief in patients with soft tissue injuries

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 30 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bupivacaine (Primary)
Indications Postoperative pain; Soft tissue injuries
Focus Adverse reactions; Registrational
Sponsors Bausch Health Companies; DURECT Corporation

Most Recent Events

11 Sep 2025 According to a Bausch Health media release, DURECT Corporation has been acquired and merged into Bausch Health Companies.
26 May 2015 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com